Boehringer Ingelheim remains on growth path, despite difficult scenario
Family-owned German drug major Boehringer Ingelheim says it grew further in the first half of 2013, despite difficult overall conditions. Net sales rose by 3.1%, currency-adjusted, compared to the same period in the previous year, to around 7.1 billion euros ($9.58 billion), a 0.7% dip in euro terms.
The main growth drivers, according to the company, were the oral anticoagulant Pradaxa (dabigatran etexilate), Trajenta (linagliptin), for type 2 diabetes, and Spiriva (tiotropium), for the treatment of chronic obstructive pulmonary disease (COPD).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze